GigaMune closes pre-seed financing round

GigaMune, a new biotech based in San Francisco, recently closed a pre-seed financing round to support its initial efforts to develop novel in vivo cell therapeutics for cancer and inherited disease. GigaMune’s technology relies on methods to search quadrillions of nucleotides for proteins such as viral receptors, new technologies for artificial intelligence to optimize protein design, and high throughput screening methods for identifying lead chimeric antigen receptors (CARs), T cell receptors (TCRs), and cell tropism antibodies.

Certain intellectual property was spun out from GigaGen, but neither GigaGen nor GigaGen’s corporate parent (Grifols) has any equity stake in GigaMune. GigaMune founders include longtime colleagues Dr. David Johnson (CEO), Dr. Matt Spindler (VP Research), and Dr. Everett Meyer (clinical adviser).

Investors in the pre-seed financing include Drs. David Johnson and Matt Spindler, Boost VC, Sand Hill Angels, BioVerge, Reinforced Ventures, Newsight Tech Angels, former Genentech executives, and former Stemcentrx executives.

The terms of the financing were undisclosed.